Continuing Pharmacy Education / CE Master List / Challenging Topics in Anticoagulation
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Challenging Topics in Anticoagulation

About this Course

UConn has developed web-based continuing pharmacy education activities to enhance the practice of pharmacists and assist pharmacists in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve. There are a total of 12 hours of CPE credit available. Successful completion of these 12 hours (13 activities) or equivalent training will prepare the pharmacist for the Anticoagulation Traineeship, which described below in the Additional Information Box.

The activities below are available separately for $17/hr or as a bundle price of $140 for all 13 activities (12 hours). These are the pre-requisites for the anticoagulation traineeship. Any pharmacist who wishes to increase their knowledge of anticoagulation may take any of the programs below.

When you are ready to submit quiz answers, go to the Blue "Take Test/Evaluation" Button.

Target Audience

Pharmacists who are interested in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve.

This activity is NOT accredited for technicians.

Pharmacist Learning Objectives

At the end of this application-based continuing education activity, the pharmacist will be able to:

  • Discuss managing techniques for challenging patient types including alcoholism, pregnancy, and patients with Antiphospholipid Antibodies Syndrome
  • Describe the discrepancy between POC testing and laboratory measurement of INR
  • Discuss the evidence for 12 week follow up visits and how to determine which patients are  appropriate
  • Evaluate anticoagulation therapy for selected challenging cases

Release Date

Released:  06/01/2022
Expires:  05/31/2025

Course Fee

$17

ACPE UAN Codes

0009-0000-22-038-H01-P

Accreditation Hours

1.0 hours of CE

Bundle Options

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Additional Information

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

Accreditation Statement

ACPE logo

The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ADD ACPE UAN 0009-0000-22-038-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

Grant Funding

There is no grant funding for this activity.

Requirements for Successful Completion

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Faculty

Michael Smith, PharmD, CACP, BCPS
East Region Clinical Manager, Pharmacy
Hartford Healthcare
William W. Backus Hospital
Norwich, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Smith has no relationship with an ineligible company and therefore has nothing to disclose.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Program Content

Program Handouts

Post Test Evaluation

View Questions for Challenging Topics in Anticoagulation

  1. Alcohol interacts with warfarin through

A             CYP450 1A2

B             Alcohol dehydrogenase

C             Interaction has not been clearly defined

D            p-Glycoprotein

 

  1. The greatest risk of fetal abnormalities related to warfarin use occurs during

A             The first trimester

B             The second trimester

C             The third trimester

D            stable throughout pregnancy

 

  1. The optimal duration of follow-up for patients receiving warfarin is:

A             Weekly

B             Monthly

C             Every 12 weeks

D            Not clearly defined in the literature

 

  1. When using enoxaparin during pregnancy for the prevention of VTE in patients who have been receiving long term warfarin therapy:

A             Use near therapeutic treatment level doses adjusted for body weight

B             Use standard prophylactic doses

 

  1. Antiphospholipid antibody syndrome:

A             Decreases the levels of Factor II and X

B             is associated with an Increase in the risk of hemorrhagic complications

C             is a viral disease

D            May interfere with the INR measurement of patients receiving warfarin

 

  1. Alcohol

A             Should be avoided at any level in all patients receiving warfarin

B             Can be managed similar to other drug interactions

C             Multiple studies on the interaction between binge drinking and warfarin have been published

D            Alcoholism is a FDA labeled contraindication to the use of warfarin

 

  1. The risk of thrombosis in pregnant women with mechanical heart valves is

A             Lowest in patients being treated with warfarin

B             Lowest in patients being treated with a LMWH

 

  1. No major group of international experts have supported the notion testing the INR in a patient receiving warfarin as little as once every 3 months

A             True

B             False

 

  1. A clinically appropriate way to monitor a patient receiving warfarin with antiphospholipid antibody syndrome is:

A             Factor II activity level

B             Factor X activity level

C             Activated Clotting Time (ACT)

D            Both A and B

 

  1. Binge drinking of alcohol in an anti-coagulated patient increase the risk of

A             Falls

B             Gastrointestinal bleeding

C             Non-compliance

D            All of the above